Cancer imaging technology company Michelson Diagnostics Ltd (MDL) has announced that it has commenced the engineering phase of its development of probes for in-vivo imaging with optical coherence tomography (OCT).

According to MDL Applications Director Dr Gordon McKenzie, more than one type of probe will start clinical testing during 2008. The probes will be suitable for a variety of applications, including research into diagnosis, treatment and monitoring of cancer of the oral cavity, oesophagus, skin, cervix, colorectal tract and lung. "All of the probes will use MDL's breakthrough multi-beam OCT technology", he said, "which will provide at least double the resolution of competing equipment, for much crisper, clearer image of clinical features."

Dr McKenzie confirmed that users of the existing EX1301 OCT Microscope will easily be able to upgrade to the in-vivo technology as soon as it is released. He also said that MDL is interested in finding clinical teams that are interested in conducting clinical trials with the in-vivo probes.

For further details, please contact Dr Gordon McKenzie, Applications Director, on +44 (0)7973 343414, Email: Gordon.McKenziemd-ltd

Higher resolution versions of the pictures are available on request from the contact above. Michelson Diagnostics Ltd is the UK's leading independent manufacturer and developer of Optical Coherence Tomography medical imaging equipment. Founded in 2006, it is based in SE London, UK. The company's highly innovative optical probe technology offers the best available sub-surface OCT images for research applications in cancer surgery guidance, surveillance and diagnosis.

michelsondiagnostics